Canadian Cancer Trials Group

This study is for women with a low-risk type of breast cancer that has spread to nearby lymph nodes or is T3N0. It compares standard care (which includes radiation to the lymph node area) against skipping that extra radiation. The goal is to see if avoiding regional radiation wor…

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This phase II trial tests whether adding the immunotherapy drug durvalumab after surgery, chemotherapy, and radiation can help prevent bladder cancer from coming back in people with muscle-invasive bladder cancer. About 82 participants will receive either durvalumab or a placebo …

This study compares two types of brachytherapy (radiation implants) for localized prostate cancer: low-dose-rate (seed) implants and high-dose-rate (temporary) implants. About 334 men will receive one of the two treatments. Researchers will measure how well each controls cancer a…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This phase 3 trial tests whether adding the experimental drug ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced ER-positive, HER2-negative breast cancer. The study enrolls 250 postmenopausal women whose cancer worsened after initial treatment w…

This study tests a new drug called CFI-402257 combined with the standard chemotherapy paclitaxel in people with advanced HER2-negative breast cancer that cannot be cured. The goal is to see if the combination works better than paclitaxel alone at slowing tumor growth. About 37 wo…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409…

This phase 2 trial tests whether a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, can slow cancer growth better than standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has stopped responding to hormone therapy.…

This phase 2 trial compares standard treatment (radiation plus chemotherapy drug cisplatin) against two experimental arms using the immunotherapy drug durvalumab with radiation, followed by either durvalumab alone or durvalumab plus another immunotherapy, tremelimumab. The study …

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help patients live longer by helping their immune system fight the cancer. Participants m…

This phase 2 trial is testing whether combining an experimental pill (CFI-400945) with an immunotherapy drug (durvalumab) can shrink tumors in 15 women with advanced triple negative breast cancer that has spread or cannot be removed. The study measures how many participants see t…

This phase 2 trial tests the drug JDQ443 in people with non-small cell lung cancer before they have surgery. The goal is to see if the drug can shrink tumors and improve outcomes. Only 4 participants are enrolled, so results are very early.

This Phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug in 28-day cycle…

This study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…

This study is testing whether giving less radiation to the lymph nodes can reduce side effects for people with low-risk HPV-related throat cancer. The goal is to see if doctors can safely skip radiation to some lymph node areas without increasing the chance of the cancer coming b…

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…